WNT5A and melanoma: Investigators extended their findings to clinical specimens as well when they demonstrated that 8 of 12 patients who relapsed while on BRAFi therapy showed increased positivity for WNT5A expression, clearly indicating the direct involvement of WNT5A in BRAFi resistance in melanoma patients.